GCIQ&A with Verici Dx CEO, Sara Barrington
In this interview, CEO Sara Barrington of (VRCI ) – an advanced medical diagnostics firm focusing on the global kidney transplant market - takes me through today’s strong H1’24 results and multiple value catalysts ahead for the business.
00:00 Recap of #VRCI’s unique technology and USPs
05:30 Ground breaking licensing deal with Thermo Fisher Scientific.
09:35 Commercialisation of Tutivia & Protega validation test
17:00 Services, placing, cash runway & outlook
Disclosure: Verici is a Vox Markets client
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.